Connection

CHRISTINE BEETON to Animals

This is a "connection" page, showing publications CHRISTINE BEETON has written about Animals.
Connection Strength

0.733
  1. Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver. PLoS One. 2023; 18(4):e0283996.
    View in: PubMed
    Score: 0.047
  2. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2211977120.
    View in: PubMed
    Score: 0.047
  3. Differences in ion channel phenotype and function between humans and animal models. Front Biosci (Landmark Ed). 2018 01 01; 23(1):43-64.
    View in: PubMed
    Score: 0.033
  4. KCa1.1 channels as therapeutic targets for rheumatoid arthritis. Expert Opin Ther Targets. 2017 12; 21(12):1077-1081.
    View in: PubMed
    Score: 0.032
  5. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 07; 180:45-57.
    View in: PubMed
    Score: 0.031
  6. Detection of Matrix Metalloproteinases by Zymography. Methods Mol Biol. 2017; 1579:231-244.
    View in: PubMed
    Score: 0.031
  7. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Mar Drugs. 2015 Jan 16; 13(1):529-42.
    View in: PubMed
    Score: 0.027
  8. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.025
  9. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013; 8(10):e76740.
    View in: PubMed
    Score: 0.025
  10. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011 Oct; 10(5):313-21.
    View in: PubMed
    Score: 0.021
  11. Isolation of mononuclear cells from the central nervous system of rats with EAE. J Vis Exp. 2007; (10):527.
    View in: PubMed
    Score: 0.016
  12. Discovery on Target 2007--CHI's Fifth Annual Conference. Ion channels. IDrugs. 2007 Dec; 10(12):851-4.
    View in: PubMed
    Score: 0.016
  13. Preparing T cell growth factor from rat splenocytes. J Vis Exp. 2007; (10):402.
    View in: PubMed
    Score: 0.016
  14. Induction and monitoring of adoptive delayed-type hypersensitivity in rats. J Vis Exp. 2007 Oct 01; (8).
    View in: PubMed
    Score: 0.016
  15. Drawing blood from rats through the saphenous vein and by cardiac puncture. J Vis Exp. 2007; (7):266.
    View in: PubMed
    Score: 0.016
  16. Induction and monitoring of active delayed type hypersensitivity (DTH) in rats. J Vis Exp. 2007; (6):237.
    View in: PubMed
    Score: 0.016
  17. Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis. J Vis Exp. 2007; (5):224.
    View in: PubMed
    Score: 0.016
  18. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17414-9.
    View in: PubMed
    Score: 0.015
  19. Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist. 2005 Dec; 11(6):550-62.
    View in: PubMed
    Score: 0.014
  20. In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene. Sci Transl Med. 2025 Feb 12; 17(785):eadk3920.
    View in: PubMed
    Score: 0.013
  21. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.
    View in: PubMed
    Score: 0.013
  22. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J Biol Chem. 2004 Dec 31; 279(53):55690-6.
    View in: PubMed
    Score: 0.013
  23. [Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers]. Rev Neurol (Paris). 2004 May; 160(5 Pt 2):S16-27.
    View in: PubMed
    Score: 0.013
  24. Magnesium increases numbers of Foxp3+ Treg cells and reduces arthritis severity and joint damage in an IL-10-dependent manner mediated by the intestinal microbiome. EBioMedicine. 2023 Jun; 92:104603.
    View in: PubMed
    Score: 0.012
  25. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem. 2003 Mar 14; 278(11):9928-37.
    View in: PubMed
    Score: 0.012
  26. Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts. Sci Rep. 2022 02 18; 12(1):2847.
    View in: PubMed
    Score: 0.011
  27. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. Mol Ther. 2020 Jun 03; 28(6):1432-1441.
    View in: PubMed
    Score: 0.010
  28. Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response. Neuron. 2019 11 20; 104(4):665-679.e8.
    View in: PubMed
    Score: 0.009
  29. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther. 2019 01 07; 21(1):6.
    View in: PubMed
    Score: 0.009
  30. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018 11 13; 138(20):2227-2242.
    View in: PubMed
    Score: 0.009
  31. Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis. J Pharmacol Exp Ther. 2018 05; 365(2):227-236.
    View in: PubMed
    Score: 0.008
  32. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Sci Rep. 2017 06 16; 7(1):3756.
    View in: PubMed
    Score: 0.008
  33. Changes in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury. J Neurotrauma. 2017 03 15; 34(6):1175-1186.
    View in: PubMed
    Score: 0.008
  34. Characterization of a novel MR-detectable nanoantioxidant that mitigates the recall immune response. NMR Biomed. 2016 10; 29(10):1436-44.
    View in: PubMed
    Score: 0.007
  35. Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep. 2015 Oct 28; 5:15776.
    View in: PubMed
    Score: 0.007
  36. N-Terminally extended analogues of the K? channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J. 2015 Jun; 282(12):2247-59.
    View in: PubMed
    Score: 0.007
  37. The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clin Immunol. 2015 Jun; 158(2):183-92.
    View in: PubMed
    Score: 0.007
  38. KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis. Arthritis Rheumatol. 2015 Jan; 67(1):96-106.
    View in: PubMed
    Score: 0.007
  39. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. Int Immunopharmacol. 2014 Oct; 22(2):427-43.
    View in: PubMed
    Score: 0.006
  40. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep; 28(9):3952-64.
    View in: PubMed
    Score: 0.006
  41. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep. 2014 Mar 28; 4:4509.
    View in: PubMed
    Score: 0.006
  42. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One. 2013; 8(11):e78712.
    View in: PubMed
    Score: 0.006
  43. Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers. PLoS One. 2012; 7(12):e52965.
    View in: PubMed
    Score: 0.006
  44. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 2012 Nov 16; 586(22):3996-4001.
    View in: PubMed
    Score: 0.006
  45. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther. 2012 Sep; 342(3):642-53.
    View in: PubMed
    Score: 0.006
  46. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep; 82(3):372-82.
    View in: PubMed
    Score: 0.006
  47. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 2012 Mar 15; 59(4):529-46.
    View in: PubMed
    Score: 0.005
  48. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun. 2011; 2:334.
    View in: PubMed
    Score: 0.005
  49. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol. 2009 Apr; 75(4):762-73.
    View in: PubMed
    Score: 0.004
  50. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29(4):602-14.
    View in: PubMed
    Score: 0.004
  51. Imaging effector memory T cells in the ear after induction of adoptive DTH. J Vis Exp. 2008 Aug 14; (18).
    View in: PubMed
    Score: 0.004
  52. The impact of the fourth disulfide bridge in scorpion toxins of the alpha-KTx6 subfamily. Proteins. 2005 Dec 01; 61(4):1010-23.
    View in: PubMed
    Score: 0.004
  53. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun; 65(6):1364-74.
    View in: PubMed
    Score: 0.003
  54. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003 Jun; 111(11):1703-13.
    View in: PubMed
    Score: 0.003
  55. Myelin basic protein-reactive T cells induce conduction failure in vivo but not in vitro. Neuroreport. 2003 Mar 03; 14(3):317-20.
    View in: PubMed
    Score: 0.003
  56. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13942-7.
    View in: PubMed
    Score: 0.003
  57. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001 Jan 15; 166(2):936-44.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.